# Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection

> **NCT01760109** · PHASE4 · COMPLETED · sponsor: **Xiangbei Welman Pharmaceutical Co., Ltd** · enrollment: 2000 (actual)

## Conditions studied

- Respiratory Tract Infections
- Urinary Tract Infections

## Interventions

- **DRUG:** Piperacillin Sodium and Sulbactam Sodium

## Key facts

- **NCT ID:** NCT01760109
- **Lead sponsor:** Xiangbei Welman Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 2000 (ACTUAL)
- **Last updated:** 2019-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01760109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01760109, "Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01760109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*